SCHEMBL18484243

SCHEMBL18484243

CCC(C)N1CC2C(N)C2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21451646 1.00
SCHEMBL25585667 0.84 GAA (0.30)
SCHEMBL20215914 0.81
SCHEMBL21451663 0.81 OPRM1 (0.32)
SCHEMBL22778775 0.79 OPRM1 (0.40)
SCHEMBL24090558 0.79 HRH3 (0.32)
Hydrochloric Acid SCHEMBL5947985 0.77
SCHEMBL22778660 0.77
SCHEMBL22778703 0.77
SCHEMBL15764116 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021116872-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR VIIV HEALTHCARE COMPANY (US) 2021-06-17 WO disclosed
EP-3831839-A2 C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS ViiV Healthcare UK (No.5) Limited (GB) 2021-06-09 EP disclosed
US-20170037059-A1 GYRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-02-09 US disclosed